Point: Were industry-sponsored rofl umilast trials appropriate? yes

Chest

Volumn 145, Issue 5, 2014, Pages 937-939

  Suissa, Samy ^a   Rabe, Klaus F ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROFLUMILAST;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; DRUG WITHDRAWAL; HUMAN; LUNG FUNCTION; MULTICENTER STUDY (TOPIC); NAUSEA; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; WEIGHT REDUCTION;

ALBUTEROL; AMINOPYRIDINES; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; BRONCHODILATOR AGENTS; FEMALE; HUMANS; MALE; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84899817826     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0112     Document Type: Note

References (13)

1. Rabe KF , Bateman ED , O'Donnell D , Witte S , Bredenbroker D , Bethke TD . Rofl umilast-an oral anti-infl ammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial . Lancet . 2005 ; 366 (9485): 563-571.
2. Calverley PM , Sanchez-Toril F , McIvor A , Teichmann P , Bredenbroeker D , Fabbri LM . Effect of 1-year treatment with rofl umilast in severe chronic obstructive pulmonary disease . Am J Respir Crit Care Med . 2007 ; 176 (2): 154-161.
3. Calverley PM , Rabe KF , Goehring UM , Kristiansen S , Fabbri LM , Martinez FJ ; M2-124 and M2-125 study groups . Rofl umilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials . Lancet . 2009; 374(9691): 685-694.
4. Fabbri LM , Calverley PM , Izquierdo-Alonso JL , et al ; M2-127 and M2-128 study groups . Rofl umilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials . Lancet . 2009; 374 (9691): 695-703.
5. Calverley PM , Anderson JA , Celli B , et al ; TORCH investigators . Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease . N Engl J Med . 2007 ; 356 (8): 775-789.
6. Tashkin DP , Celli B , Senn S , et al ; UPLIFT Study Investigators . A 4-year trial of tiotropium in chronic obstructive pulmonary disease . N Engl J Med . 2008 ; 359 (15): 1543-1554.
7. Aaron SD , Vandemheen KL , Fergusson D , et al ; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium . Tiotropium in combination with placebo, salmeterol, or fl uticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial . Ann Intern Med . 2007; 146 (8): 545-555.
8. Suissa S , Ernst P , Vandemheen KL , Aaron SD . Methodological issues in therapeutic trials of COPD . Eur Respir J . 2008 ; 31 (5): 927-933.
9. Kesten S , Plautz M , Piquette CA , Habib MP , Niewoehner DE . Premature discontinuation of patients: a potential bias in COPD clinical trials . Eur Respir J . 2007 ; 30 (5): 898-906.
10. Suissa S . Lung function decline in COPD trials: bias from regression to the mean . Eur Respir J . 2008 ; 32 (4): 829-831.
11. Suissa S . Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease . Am J Respir Crit Care Med . 2006 ; 173 (8): 842-846.
12. Wouters EF , Bredenbroker D , Teichmann P , et al . Effect of the phosphodiesterase 4 inhibitor rofl umilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus . J Clin Endocrinol Metab . 2012 ; 97 (9): E1720-E1725.
13. White WB , Cooke GE , Kowey PR , et al . Cardiovascular safety in patients receiving rofl umilast for the treatment of COPD .Chest . 2013 ; 144 (3): 758-765.